Program
PRMT5 Inhibitor BGB-58067
Also written as “BGB-58067”, “BGB-58067 Tablet (F-01 Formulation)” and “BGB-58067 Tablet (F-02 Formulation)”.
Its studies are led by BeOne Medicines.
Furthest: phase 1, since Sep 6, 20242 company-led studies, 2 open or runningNext primary completion: Jul 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 22 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | Jul 1, 2027phase 1 · NCT07712640 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 6, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06589596 · 695 planned · United States, Australia, Brazil and more
- Jul 9, 2026Phase 1 study in Healthy VolunteersNCT07712640 · 32 planned · Australia
- Oct 20, 2026Primary completion moved from 2027-09-30 to 2028-08-31Date moved laterphase 1 · +11 months · NCT06589596
Ahead
- Jul 1, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07712640
- Aug 31, 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06589596
TargetBeta
PRMT5 →read by rule
“A methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 10 |
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 2 |
| JBI-778rule | jubilant-therapeutics-india-limited | phase 2 | 2 |
| PRMT5 Inhibitor TNG456rule | tango-therapeutics-inc | phase 2 | 1 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712640Healthy Volunteers · Australia | 1 | Recruiting | Jul 1, 2027 | 32 |
| NCT06589596Advanced Solid Tumor · United States, Australia, Brazil and more | 1 | Recruiting | Aug 31, 2028 | 695 |
How it is read
Names in the registry
- “BGB-58067”, 1 entry
- “BGB-58067 Tablet (F-01 Formulation)”, 1 entry
- “BGB-58067 Tablet (F-02 Formulation)”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.